Sign Out
Pregnancy: Based on available data, an increased risk of teratogenic effects has not been observed with Montelukast use in pregnancy. Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. When clinically indicated, treatment with Montelukast should not be withheld during pregnancy.
Breastfeeding considerations: Montelukast is present in breast milk. The decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Patients with asthma should be encouraged to breastfeed their infants.
